Despite limited to short and midterm outcomes, valve‐in‐valve (ViV) transcatheter aortic valve implantation (TAVI) has emerged as a valid alternative to re‐surgical aortic valve replacement (re‐SAVR) for high‐ and intermediate‐risk… Click to show full abstract
Despite limited to short and midterm outcomes, valve‐in‐valve (ViV) transcatheter aortic valve implantation (TAVI) has emerged as a valid alternative to re‐surgical aortic valve replacement (re‐SAVR) for high‐ and intermediate‐risk patients with degenerated surgical bioprosthesis.
               
Click one of the above tabs to view related content.